Biotechnology company NeuroBo Pharmaceuticals, Inc. (NRBO) announced Wednesday the receipt of Safety Review Committee (SRC) approval, recommending that the two-part Phase 2a trial of DA-1241 can continue without modification following a blinded safety review of the first six months of study conduct.